AQST
MaterialsAquestive Therapeutics Inc
$4.23+0.05 (+1.20%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AQST Today?
No stock-specific AI insight has been generated for AQST yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$526M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding124.3M
AQST News
38 articles- Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·May 6, 2026
- Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ETYahoo Finance·May 6, 2026
- Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·May 4, 2026
- Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff RoleGlobeNewswire Inc.·Apr 30, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 27, 2026
- AQST DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQSTGlobeNewswire Inc.·Apr 26, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 23, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQSTGlobeNewswire Inc.·Apr 21, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Eos Energy Enterprises, Inc. Of Class Action Lawsuit and Upcoming Deadlines – EOSEGlobeNewswire Inc.·Apr 21, 2026
- ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQSTGlobeNewswire Inc.·Apr 19, 2026
- AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law FirmGlobeNewswire Inc.·Apr 17, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 16, 2026
- Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff RoleGlobeNewswire Inc.·Apr 13, 2026
- ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQSTGlobeNewswire Inc.·Apr 10, 2026
- FBRT DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Franklin BSP Realty Trust, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FBRTGlobeNewswire Inc.·Apr 10, 2026
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarYahoo Finance·Apr 9, 2026
- Holzer & Holzer, LLC Reminds Investors of Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Aquestive Therapeutics, Inc. (AQST), Nektar Therapeutics (NKTR), and Eos Energy Enterprises, Inc. (EOSE)GlobeNewswire Inc.·Apr 6, 2026
- AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Stock Dropped Over 37 Percent: Levi & KorsinskyGlobeNewswire Inc.·Apr 6, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 6, 2026
- Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3Yahoo Finance·Mar 31, 2026
- Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual FilmYahoo Finance·Mar 30, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages Franklin BSP Realty Trust, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FBRTGlobeNewswire Inc.·Mar 29, 2026
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQSTGlobeNewswire Inc.·Mar 29, 2026
- Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. InvestorsGlobeNewswire Inc.·Mar 26, 2026
- Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance OfficerYahoo Finance·Mar 20, 2026
- Aquestive Therapeutics Targets Q3 Anaphylm Resubmission After FDA CRL Flags Human Factors, PK DataMarketbeat·Mar 11, 2026
- Aquestive Therapeutics Targets Q3 Anaphylm FDA Resubmission After CRL, Details Launch Plans at Leerink ConfMarketbeat·Mar 10, 2026
- Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 9, 2026
- Aquestive Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 5, 2026
- Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Legal ...Yahoo Finance·Mar 5, 2026
- Aquestive Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 5, 2026
- Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key MetricsYahoo Finance·Mar 4, 2026
- Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 4, 2026
- Aquestive Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 4, 2026
- Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 4, 2026
- Harrow (HROW) Misses Q4 Earnings EstimatesYahoo Finance·Mar 2, 2026
- Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer ConferenceMarketbeat·Feb 26, 2026
All 38 articles loaded
Price Data
Open$4.17
Previous Close$4.18
Day High$4.33
Day Low$4.14
52 Week High—
52 Week Low—
Fundamentals
Market Cap$526M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding124.3M
About Aquestive Therapeutics Inc
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—